Managed access opens overseas cancer therapy for U.S. dog case

CURRENT BRIEF VERSION: VMD Sciences said it helped a U.S. veterinary oncologist legally import an EMA-approved tyrosine kinase inhibitor for an 8-year-old dog with metastatic mast cell cancer through the company’s global Managed Access Program. According to the company’s February 3, 2026 announcement, the patient, Jetta, had exhausted available options in the U.S., and VMD Sciences supported Dr. Seth Glasser in navigating the regulatory pathway for compliant importation of a cancer therapy not marketed domestically. The case builds on the company’s broader push around veterinary expanded or managed access, which it has framed as a way to bridge gaps when approved local therapies aren’t available or don’t fit the clinical need. (morningstar.com)

Why it matters: For veterinary professionals, the story is less about a single dog than about access. Canine mast cell tumors are among the most common cancers seen in practice, and tyrosine kinase inhibitors already play an established role in unresectable, recurrent, or metastatic disease. In the U.S., approved options include toceranib phosphate, while Europe also has access to masitinib for certain mast cell tumors. At the same time, mast cell tumors can be deceptively hard to identify early because they often resemble routine skin masses, which is why diagnostics are also moving forward: IDEXX said it plans to add mast cell tumor detection to its Cancer Dx Panel in mid-2026 without changing sample requirements or the usual two- to three-day turnaround, and to add in-clinic FNA cytology for mast cell tumors on its inVue Dx Cellular Analyzer for same-visit assessment. A managed access route could matter in edge cases where a patient has progressed, can’t tolerate available therapy, or may benefit from a product that’s approved abroad but not in the U.S. And if more dogs reach oncology care, supportive care also matters: the FDA has renewed conditional approval of crofelemer delayed-release tablets (Canalevia-CA1) for chemotherapy-induced diarrhea in dogs through December 21, 2026, preserving an indication-specific option that may help patients stay on treatment. That said, this remains a company-reported case, not a clinical trial readout, so it doesn’t establish comparative efficacy or safety. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for whether more U.S. oncologists use managed access pathways in refractory cancer cases, whether newer mast cell tumor diagnostics gain traction in general practice and referral settings, and whether regulators or sponsors move any of these overseas oncology products toward formal U.S. veterinary approval. Supportive-care developments matter too, including whether Jaguar Health converts Canalevia-CA1 from final-year conditional approval to full approval after its ongoing effectiveness study. (businesswire.com)